BioTuesdays Feature Articles | Life Sciences News

Feature

Micromedic seeking diagnostic partners on multiple fronts

By Len Zehr With approvals in Europe and Israel for its CellDetect non-invasive test for recurrence of bladder cancer, Micromedic Technologies (TASE:MCTC) is seeking FDA approval for a pivotal trial expected to begin in...

October 25, 2016

Feature

Immunovaccine targets three clinical milestones

By Len Zehr Immunovaccine (OTCQX:IMMVF; TSX:IMV) expects to report three clinical milestones for its killer T cell activation vaccine platform, DepoVax, in ovarian and HPV cancers in the next 12 months. “Our DepoVax...

October 18, 2016

Feature

William Blair analyst discusses Hep B space

By Len Zehr As a partner and biotechnology analyst with William Blair & Co., Y. Katherine Xu was recognized in 2010 by the Financial Times/StarMine “World’s Top Analysts” listing, ranking No. 7 overall for stock...

October 11, 2016

Feature

Mesoblast developing multiple cell-based products

By Len Zehr Mesoblast (NASDAQ:MESO; ASX:MSB) has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells (MLCs), to establish a broad portfolio of...

October 4, 2016

Feature

Knight Therapeutics “to get real” as it builds its commercial operations

By Len Zehr In the more than 30 months since its startup, Knight Therapeutics (TSX:GUD) has shown an uncanny knack for raising equity at increasing valuations, building a portfolio of some 20 innovative products for its...

September 20, 2016

Feature

Mateon taking VDAs in new direction against cancer

By Len Zehr Mateon Therapeutics (NASDAQ:MATN) is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal tumor blood vessels, which supply nutrients to cancer cells, with an initial clinical focus...

September 13, 2016

Feature

Lupus Foundation puzzled by negative reaction to Aurinia data

By Len Zehr As president and CEO of The Lupus Foundation of America (LFA), a role she has held for 15 years, Sandra Raymond is an outspoken advocate for the plight of lupus patients. She has worked with the board of...

September 6, 2016

Feature

BioSyent to target international markets

By Len Zehr BioSyent (OTC:BIOYF; TSX-V:RX) is actively building its international pharmaceutical sales and marketing business, adding products licensed and sold internationally to products already being shipped from...

August 30, 2016

Feature

Oramed hopes to start Phase 3 oral insulin trial next year

By Len Zehr After posting positive Phase 2b results with its oral insulin drug candidate, ORMD-0801 in Type 2 diabetes, Oramed Pharmaceuticals (NASDAQ:ORMP) hopes to meet with the FDA before the end of 2016 to discuss...

August 23, 2016

Feature

In conversation with Ben Haynor

By Len Zehr As a senior research analyst with Feltl & Co. for the past six years, Ben Haynor ranked second in the May 2013 Wall Street Journal Best on the Street publication in the Medical Equipment and Supplies...

August 16, 2016

Feature

Parvus developing Navacims to treat autoimmune diseases

By Len Zehr Closely-held Parvus Therapeutics is developing a broad therapeutic platform, called Navacims, to treat autoimmune diseases through in vivo expansion and activation of disease-specific regulatory T-cells (T...

August 9, 2016

Feature

Triumvira targeting cancer with customized T cells

By Len Zehr Closely-held Triumvira Immunologics is developing a novel platform to engineer the immune system’s T cells to attack cancer using proprietary T Cell-Antigen Couplers (TACs). “TACs were designed to use the...

July 26, 2016

Feature

In conversation with Dr. Paul Lem

By Len Zehr As CEO and a co-founder of Spartan Bioscience, Dr. Paul Lem has led the closely-held company through FDA and Health Canada approval of the Spartan RX CYP2C19 System, a breakthrough technology that provides...

July 19, 2016

Feature

Braeburn taking path as pill-free pharma company

By Len Zehr Closely-held Braeburn Pharmaceuticals, which in late May received FDA approval to market the first ever six-month implant of buprenorphine for opioid dependence, is developing a portfolio of long-acting...

July 12, 2016

Feature

Merus Labs moving up the value chain

By Len Zehr After an 18-month company transformation under new CEO, Barry Fishman, Merus Labs International (NASDAQ:MSLI; TSX:MSL) is now ready to in-license new pharmaceutical products, in addition to optimizing...

July 5, 2016

Feature

Juniper Pharma’s lidocaine vaginal gel data due in Q3

By Len Zehr Juniper Pharmaceuticals (NASDAQ:JNP) expects to report results in the third quarter from a Phase 2b clinical trial of its 10% lidocaine bioadhesive vaginal gel, COL-1077, a local anesthetic for pain from...

June 28, 2016

Feature

S1 Biopharma to start Phase 2b study in female HSDD by yearend

By Len Zehr Closely-held S1 Biopharma expects to initiate a Phase 2b study at the end of the year with its lead product candidate for female hypoactive sexual desire disorder (HSDD), Lorexys, and a Phase 2a program with...

June 14, 2016

Feature

ESSA Pharma takes unique approach to prostate cancer

By Len Zehr A marine sponge, Geodia lindgreni, native to Papua New Guinea may hold the key to a new approach in the treatment of prostrate cancer by ESSA Pharma (NASDAQ:EPIX; TSX:EPI). “Our scientific founders from the...

June 7, 2016

Feature

Lipocine advancing pipeline, PDUFA for oral TRT

By Len Zehr With a PDUFA date of June 28 for an FDA decision on its oral testosterone replacement therapy (TRT) product candidate, TLANDO, Lipocine’s (NASDAQ:LPCN) next two pipeline product candidates are advancing...

May 31, 2016

Feature

Delivra implementing U.S. expansion strategy for topical creams

By Len Zehr The major initiative for Delivra (TSX-V:DVA) in 2016 is to introduce its flagship LivRelief topical pain and nerve creams to the U.S. market, initially through a U.S. web store and Amazon, and then through...

May 24, 2016

Feature

ARIAD hopes to launch second oncology drug in early 2017

By Len Zehr ARIAD Pharmaceuticals (NASDAQ:ARIA) is hoping to receive FDA approval to commercialize in early 2017 its second orphan oncology product, brigatinib, for the treatment of certain genetic forms of non-small...

May 17, 2016

Feature

Profound Medical readies pivotal clinical trial of TULSA-PRO

By Len Zehr After receiving CE Mark approval last month of its minimally invasive transurethral ultrasound technology for the ablation of benign and malignant prostate tissue, known as TULSA-PRO, Profound Medical (TSX...

May 3, 2016

Subscribe